NuVasive Appoints New Chief Financial Officer and Announces Additional Manageme...(or devices including risks that such pro...),Health

Date:11/6/2009

or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Contact:                             Investors:
    Kevin C. O'Boyle                     Patrick F. Williams
    EVP & Chief Financial Officer        Vice President, Finance & Investor
    NuVasive, Inc.                       Relations
    858-909-1998                         NuVasive, Inc.
    investorrelations@nuvasive.com       858-638-5511
                                         investorrelations@nuvasive.com
    Media:
    Jason Rando
    The Ruth Group
    646-536-7025
    jrando@theruthgroup.com

SOURCE NuVasive, Inc.

'/>"/>

SOURCE NuVasive, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference
2. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
3. NuVasive to Present at the JMP Securities Healthcare Focus Conference
4. Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors
5. Company Appoints New SVP, Marketing for PBM Business
6. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
7. Qforma Appoints Erin McLaughlin as Director, Field Operations
8. VitaminSpice Appoints Dr. Richard F. Seelig as Director
9. Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs
10. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
11. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs